

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Briffa, JF;O'Dowd, R;Moritz, KM;Romano, T;Jedwab, LR;McAinch, AJ;Hryciw, DH;Wlodek, ME

Title:

Uteroplacental insufficiency reduces rat plasma leptin concentrations and alters placental leptin transporters: ameliorated with enhanced milk intake and nutrition

Date:

2017-06-01

Citation:

Briffa, J. F., O'Dowd, R., Moritz, K. M., Romano, T., Jedwab, L. R., McAinch, A. J., Hryciw, D. H. & Wlodek, M. E. (2017). Uteroplacental insufficiency reduces rat plasma leptin concentrations and alters placental leptin transporters: ameliorated with enhanced milk intake and nutrition. *Journal of Physiology*, 595 (11), pp.3389-3407. <https://doi.org/10.1113/JP273825>.

Persistent Link:

<https://hdl.handle.net/11343/292711>

Uteroplacental insufficiency reduces rat plasma leptin concentrations and alters placental leptin transporters: ameliorated with enhanced milk intake and nutrition

Jessica F. Briffa¹, Rachael O'Dowd¹, Karen M Moritz², Tania Romano³, Lisa R Jedwab¹, Andrew J. McAinch⁴, Deanne H. Hryciw^{1*} and Mary E. Wlodek^{1*}

¹Department of Physiology, The University of Melbourne, Victoria 3010, Australia

²School of Biomedical Sciences, The University of Queensland, St. Lucia, QLD, 4072, Australia

³Department of Human Biosciences, LaTrobe University, Bundoora, VIC, 3083, Australia

⁴Centre For Chronic Disease, College of Health and Biomedicine, Victoria University, St Albans, VIC 3021, Australia

* Co-senior authorship

To whom correspondence should be address: Prof Mary Wlodek, Department of Physiology, The University of Melbourne, Parkville, VIC 3010, Australia. Phone: 61 3 9035 9923 Fax: 61 3 8344 5818 email: m.wlodek@unimelb.edu.au

Running Title – Cross-fostered rats born small have increased plasma leptin & milk intake

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1113/JP273825](#).

Keywords – growth restriction, leptin, placenta, mammary, milk, cross-fostering

Key points

- Uteroplacental insufficiency compromises maternal mammary development, milk production and pup organ development. Cross-fostering improves pup growth, organ development and prevents adult diseases in growth restricted offspring by enhancing postnatal nutrition.
- Leptin is transported to the fetus from the mother by the placenta. We report reduced plasma leptin concentrations in Restricted fetuses, which is associated with sex-specific alterations in placental leptin transporter expression.
- Pup plasma leptin concentrations were also reduced during suckling, which may suggest reduced milk leptin transport or leptin reabsorption.
- Mothers suckled by Restricted pups had impaired mammary development and changes in milk fatty acid composition with no alterations in milk leptin. Cross-fostering restored pup plasma leptin concentrations, which may be correlated to improved milk composition and intake.
- Increased plasma leptin and altered milk fatty acid composition in Restricted pups suckling mothers with normal lactation may improve postnatal growth and prevent adult diseases.

Abstract

Uteroplacental insufficiency reduces birth weight and adversely affects fetal organ development, increasing adult disease risk. Cross-fostering improves postnatal nutrition and restores these deficits. Mothers with growth restricted pups have compromised milk production and composition, however the impact cross-fostering has on milk production and composition is unknown. Plasma leptin concentrations peak during the completion of organogenesis, which occurs postnatally in rats. Leptin is transferred to the fetus via the placenta and to the pup via the lactating mammary gland. This study investigated the effect of uteroplacental insufficiency on pup plasma leptin concentrations and placental leptin transporters. We additionally examined if cross-fostering improves mammary

development, milk composition and pup plasma leptin concentrations. Fetal growth restriction (Restricted) was induced by bilateral uterine vessel ligation surgery on gestation day 18 in Wistar Kyoto rats. Restricted fetuses had reduced plasma leptin concentrations, persisting throughout lactation, and sex-specific alterations in placental leptin transporters. Mothers' suckled by Restricted pups had impaired mammary development, altered milk fatty acid composition and increased plasma leptin concentrations despite no changes in milk leptin. Pup milk intake was reduced in Restricted pups suckling uteroplacental insufficiency surgery mothers compared to Restricted pups suckling sham operated mothers. Cross-fostering Restricted pups onto a sham operated mother improved postnatal growth and restored plasma leptin concentrations compared to Restricted pups suckling uteroplacental insufficiency surgery mothers. Uteroplacental insufficiency alters leptin homeostasis that is ameliorated with cross-fostering and enhanced milk fatty acid composition and consumption, which may protect the pups from developing adverse health conditions in adulthood.

Abbreviations list

Akt, protein kinase B; AMPK, AMP-activated protein kinase; *Control-on-Control*, Control pups suckling sham operated mothers; *Control-on-Restricted*, Control pup suckling uteroplacental insufficiency surgery mother; E, embryonic day; ELISA, enzyme-linked immunosorbent assay; FAMES, fatty acid methyl esters; FIL, feedback inhibitor of lactation; JAK, Janus kinase; LC-MUFA, long chain monounsaturated fatty acids; LC-PUFA, long chain polyunsaturated fatty acids; mTOR, mammalian target of rapamycin; ObR, leptin receptor; PI3K, phosphoinositide-3-kinase; PN, postnatal; PTHrP, parathyroid hormone related peptide; *Restricted-on-Control*, Restricted pup suckling a sham operated mother; *Restricted-on-Restricted*, Restricted pup suckling a uteroplacental insufficiency; SOCS, suppressor of cytokine signalling; SRY, sex-determining region Y; STAT, signal transducers and activators of transcription; WKY, Wistar Kyoto.

Introduction

Being born small is a complication of 10% of pregnancies and results from a reduction in the delivery of nutrients and oxygen across the placenta to the growing fetus, which in Western cultures is commonly due to uteroplacental insufficiency (Barker *et al.*, 1989). Exposure to adverse conditions during critical periods of development alters the trajectory and growth of organs resulting in structural organ changes (McMillen & Robinson, 2005; Barker, 2007; Gluckman *et al.*, 2008; Morton *et al.*, 2016). Both epidemiological and experimental studies have identified that growth restriction

impairs nephron (Hughson *et al.*, 2003; Wlodek *et al.*, 2007), cardiac (Black *et al.*, 2012) and pancreas development (Siebel *et al.*, 2010) and programs male adult onset hypertension (Koklu *et al.*, 2007; Wlodek *et al.*, 2007) and glucose intolerance (Siebel *et al.*, 2008), which is prevented with early accelerated growth (Lucas *et al.*, 1997; Eriksson *et al.*, 2000; Wlodek *et al.*, 2007).

The adipokine leptin plays a role in normal pregnancy adaptations and fetal development (Attig *et al.*, 2011; Briffa *et al.*, 2015b). Leptin is predominantly secreted by white adipose tissue, the placenta (to a lesser extent in rodents) and mammary epithelium during lactation (Landt *et al.*, 2003; Hama *et al.*, 2004), and is transported from the mother to the fetus via the placenta (Smith & Waddell, 2003). After parturition it is not known whether the main source of offspring leptin is due to offspring leptin production from adipose stores or from the maternal milk supply. Research identified that milk leptin concentrations are elevated during peak lactation, which correlates with the period of rapid infant weight gain and height (Doneray *et al.*, 2009), suggesting that leptin may play a role in regulating infant growth. Humans born growth restricted have reduced plasma leptin concentrations at birth (Koklu *et al.*, 2007; Nezar *et al.*, 2009) suggesting that there may be reduced placental leptin transportation. Leptin transportation and signalling occurs by the leptin receptor (ObR) that activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway (Banks *et al.*, 2000), or the scavenger receptor megalin that activates the phosphoinositide-3-kinase (PI3K) pathway (Ahima *et al.*, 1996; Briffa *et al.*, 2014; Briffa *et al.*, 2015a). The mammalian target of rapamycin (mTOR) is downstream of the PI3K pathway and, under low glucose conditions, is inhibited by AMP-activated protein kinase, which promotes autophagy (Kim *et al.*, 2011) and we have previously demonstrated that leptin can modulate AMPK expression in the renal proximal tubule (opossum kidney cells) (Ahima *et al.*, 1996; Briffa *et al.*, 2014; Briffa *et al.*, 2015a). Critically, both of these signalling pathways regulate cellular growth, proliferation and differentiation.

In humans and most mammalian species there is a plasma leptin surge that is associated with the completion of organ maturation and development, which occurs postnatally in the rat (Ahima *et al.*, 1998). Leptin antagonism in rats during the leptin surge (postnatal day (PN) 2 – PN13) reduces glomerular number and size, and alters pancreatic, ovarian and thymic development (Attig *et al.*, 2011). Therefore it is possible that the impaired organogenesis in pups born small may be causally associated with their reduced plasma leptin concentrations. Interestingly in rodent models of maternal undernutrition there is a reduction in the postnatal plasma leptin surge (Delahaye *et al.*,

2008), as well as reductions in placental ObR (Nüsken *et al.*, 2011), protein kinase B (Akt), mTOR and STAT3 (Rosario *et al.*, 2011) expression, which is not observed in a model of bilateral uterine vessel ligation (Nüsken *et al.*, 2011). This highlights that different models of growth restriction influences fetal leptin concentrations and placental leptin signalling targets in a similar or a different manner. A major limitation of the studies described above is that they pooled the placentae and did not determine differences between fetal sex, which is important due to the work by (Cuffe *et al.*, 2012; Cuffe *et al.*, 2014). Changes in placental leptin signalling through ObR and megalin following uteroplacental insufficiency, the major cause of growth restriction in the Western world, are unknown.

Postnatal growth rate and development is directly proportional to the quality and quantity of milk produced by the mammary gland, which has a major influence on disease risk. Adequate fatty acid intake during pregnancy and lactation is essential for normal pup growth and development (Mennitti *et al.*, 2015). Uteroplacental insufficiency in rat dams results in lower circulating progesterone concentrations and dams experience premature lactogenesis II, characterized by an increase in α -lactalbumin in late pregnancy (O'Dowd *et al.*, 2008). Additionally, uteroplacental insufficiency dams have reduced mammary parathyroid hormone related protein (PTHrP) (O'Dowd *et al.*, 2008), which appears to have important roles in mammary branching morphogenesis, calcium transport from the maternal plasma to milk and regulating mammary blood flow (Philbrick *et al.*, 1996). As a consequence mammary development during pregnancy and mammary gland function after birth are impaired further slowing postnatal growth (O'Dowd *et al.*, 2008). We have previously demonstrated that improving the early lactational nutrition, by cross-fostering growth restricted pups onto a mother with normal lactation, restores nephron (Wlodek *et al.*, 2007) and cardiomyocyte numbers (Black *et al.*, 2012), pancreas morphology (Siebel *et al.*, 2010), and prevents hypertension (Wlodek *et al.*, 2007) and glucose intolerance (Siebel *et al.*, 2008). As leptin is transferred to the pup by the milk (Dundar *et al.*, 2005; Doneray *et al.*, 2009), it is possible that this restoration of organogenesis following cross-fostering is due to enhanced leptin delivery as a result of improved postnatal nutrition.

Therefore the aim of this study was to characterise the effect uteroplacental insufficiency has on placental leptin transporter expression. We additionally investigated the effect uteroplacental insufficiency has on maternal and offspring plasma leptin concentrations and milk leptin

concentrations, and whether this is restored by improving pup postnatal nutritional intake through cross-fostering. Finally, we characterised the effect cross-fostering has on milk consumption and mammary development. As there are known sex-specific disease programming effects (Moritz *et al.*, 2009; Tare *et al.*, 2012; Wadley *et al.*, 2013), a further aim was to establish whether sex-specific differences existed.

Methods

Ethics approval

All experiments were approved by The University of Melbourne's animal experimentation ethics sub-committee (AEC: 0004138 and 02081) and the La Trobe animal ethics committee (AEC: 12-42) following the National Health and Medical Research Councils (NHMRC) Australian code for the care and use of animals for scientific purposes. The investigators understand the ethical principles under which the journal operates and that our work complies with the animal ethics checklist. Female Wistar Kyoto (WKY) rats (9 to 13 wks of age) were obtained from the Animal Resources Centre (Canning Vale, WA, Australia) and provided with a 12-hr light/dark cycle at 19-22°C with *ad libitum* access to food and water. Rats were mated and surgery was performed on day 18 of gestation (term = 22 days) as described previously (Wlodek *et al.*, 2005). Briefly, F0 pregnant rats were randomly allocated to a sham (offspring termed Control) or uteroplacental insufficiency (offspring termed Restricted) group and were anaesthetized with 4% isoflurane and 650 ml.min⁻¹ oxygen flow (reduced to 3.2% isoflurane and 250 ml.min⁻¹ oxygen flow when suturing to aid in the animals recovery). Uteroplacental insufficiency was induced by bilateral uterine vessel (artery and vein) ligation, which restricts blood supply and nutrient delivery to the fetuses. Sham surgery for the control group was performed in the same manner, except uterine vessels were not ligated.

Study 1: Developmental timeline

At embryonic day (E) 20 one cohort of pregnant rats were anesthetized (Ketamine (50 mg/kg; Parnell Laboratories, Alexandria, NSW, Australia) and Ilium Xylazil-20 (10 mg/kg; Troy Laboratories, Glendenning, NSW, Australia)), their uterus was exposed and amniotic fluid collected (n = 10 – 20 mothers/group). Fetuses and pups at PN1 and PN7 (in separate cohorts) were weighed, sex visually determined by the anogenital distance and were killed by decapitation. In a final cohort at PN35,

offspring were weighed, anesthetized (Ketamine (50 mg/kg) and Ilium Xylazil-20 (10mg/kg)) and euthanized via cardiac puncture. Blood was collected at the time of *post mortem*, which was pooled in each litter at E20 or separated by sex in the postnatal ages. The placentae at E20 were weighed, frozen immediately in liquid nitrogen and stored at -80°C for subsequent analysis. For tissue extraction, placentae associated with one male and one female from each litter were chosen with a body weight that was the closest to the litter average, with each sample representing a single animal (i.e. n = 1). Additionally, maternal rats were weighed, anesthetized (Ketamine (50 mg/kg) and Ilium Xylazil-20 (10 mg/kg)) and euthanized via cardiac puncture, with blood collected for subsequent analysis.

To ensure accurate sex was recorded for pups at E20 a portion of the placenta (labyrinth zone; fetal interface) was incubated in proteinase K (Life Technologies; Mulgrave, Vic, Australia) overnight at 55°C to extract DNA, as described previously (Cuffe *et al.*, 2012). 'Real - time' polymerase chain reaction (PCR) was then performed for sex-determining region Y (SRY) using a commercially available TaqMan probe (Rn04224592_u1; NM_012772.1) (Life Technologies).

Placenta 'real - time' PCR

RNA was extracted from labyrinth and junctional zone placental regions using the Precellys 24 homogenizer (Bertin Technologies; Aix en Provence, France) with CK14 ceramic beads and TRIzol (Life Technologies) using a commercially available kit (Norgen; Cambridge, ON, Canada). First strand cDNA was generated from 400 ng RNA using the RT² HT First Strand Kit (Qiagen; Chadstone, VIC, Australia), according to the manufactures instructions. 'Real - time' PCR was then conducted using SYBR green as the fluorescent agent. Custom RT² Profiler PCR Arrays were designed and manufactured by Qiagen for the following leptin transporters and signalling targets of interest. Leptin (NM_013076), ObR (NM_012596), JAK2 (NM_031514), STAT3 (NM_012747), STAT5a (NM_017064), suppressor of cytokine signalling 3 (SOCS3; NM_053565), megalin (NM_030827), PI3K (NM_001106723), Akt3 (NM_031575), mTOR (NM_019906), AMPK α (NM_019142) and AMPK β (NM_022627). To compensate for variations in RNA input amounts and reverse transcriptase efficiency, mRNA abundance of the genes of interest were normalized to the housekeeping gene Succinate Dehydrogenase subunit A (SDHA; NM_130428). HotStart DNA Taq Polymerase was activated by heating the mixture to 95°C for 10 mins, then 'real - time' PCR reactions were ran for 40 cycles of 95°C for 15 sec and 60°C for 60 sec. Relative changes in mRNA abundance was quantified

using the $2^{-\Delta\Delta CT}$ method and reported in arbitrary units normalized to Control male values for the junctional zone and labyrinth. SDHA values were not different between sexes and treatments.

Placental protein extraction and Western blot analysis

Membrane fractions of protein were extracted from 50 mg of placental labyrinth tissue (Gallo *et al.*, 2016). 20 μ g of membrane lysate were separated on a 5% Tris-Glycine eXtended (TGX) Stain-Free gels (Bio-Rad Laboratories; Gladesville, NSW, Australia) and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories). Membranes were probed with megalin antibody (1:1000, Santa Cruz Biotechnology; Dallas, TX, United States of America). Densitometric analysis of the banding was performed using ChemiDoc MP with ImageLab Software (Bio-Rad Laboratories). Protein expression of interest were normalized relative to Stain-Free total protein (Parviainen *et al.*, 2013) and expressed as values relative to Control male.

Study 2: Cross-fostering protocol

In a separate cohort, Restricted and Control pups were cross-fostered 1 day after birth (PN1) onto separate mothers (sham operated or uteroplacental insufficiency surgery mothers) to yield four treatment groups (*Control-on-Control*; *Control-on-Restricted*; *Restricted-on-Control*; *Restricted-on-Restricted*; $n = 12 - 18$ mothers/group) as previously described (Wlodek *et al.*, 2007; Dickinson *et al.*, 2016). Each experimental group had an even pup sex ratio. On the morning of PN6 (mammary development/function, milk composition and calcium studies) and PN7 (plasma leptin analysis), pups were removed from their mother and weighed. Pups were killed via decapitation and blood collected (pooled at PN6 and separated by sex PN7). Aprotinin (Sigma-Aldrich; Castle Hill, NSW, Australia) was added to the tubes used for plasma PTHrP analysis (PN6) (Wlodek *et al.*, 2000). One pup per litter was frozen whole and stored at -20°C for body calcium analysis (PN6). Pup stomach contents were collected (PN6) for fatty acid analysis. Mothers were anaesthetized 4-6 hours after removal of the pup to allow milk to accumulate and milk was collected following gentle massage of the left mammary gland and teats without the need for hormonal stimulation (Wlodek *et al.*, 2003). Mothers were anesthetized (Ketamine (50 mg/kg) and Ilium Xylazil-20 (10 mg/kg)) and euthanized by cardiac puncture with blood collected for subsequent analysis. The mammary glands were dissected,

weighed and the right mammary gland snap frozen in liquid nitrogen or fixed in 10% neutral buffered formalin (Perrigo; Balcatta, WA, Australia) for histological analysis.

In another cohort, pups were weighed from birth to weaning (PN35) to determine pup growth and milk intake. Pups were weighed during a 1-hour maternal separation period followed by a 3-hour re-feeding period. Milk intake was calculated as a percentage of pup body weight (O'Dowd *et al.*, 2008) and the area under the milk intake curve was calculated between PN3 and PN17 as an index of milk consumption.

Mammary 'real-time' PCR and histology

'Real-time' PCR was used to quantitate milk protein gene expression on PN6 as described previously (O'Dowd *et al.*, 2008). RNA was extracted from frozen mammary tissue using the Qiagen RNeasy kit. 'Real-time' PCR was performed using TaqMan as the fluorescent agent against the milk protein genes PTHrP (forward primer: 5'- GAG GGC AGA TAC CTA ACT CAG GAA-3'; reverse primer: 5'- TTC CCG GGC GTC TTG A-3'; probe: VIC 5'- AAC AAG GTG GAG ACG TAC AAA GAG CAG CC-3'; NM_012636.1) (Life Technologies), β -casein (Rn00567460_m1; J00711.1) (Life Technologies) and α -lactalbumin (Rn00561447_m1; NM_012594.1) (Life Technologies). Ribosomal 18S (forward primer: 5'- CGG CTA CCA CAT CCA AGG AA -3'; reverse primer: 5'- GCT GGA ATT ACC GCG GCT -3'; probe: VIC 5'- TGC TGG CAC CAG ACT TGC CCT C -3'; NM_012636.1) (Life Technologies) was used as an endogenous control and multiplexed with the milk protein genes. For the relative quantification of gene expression, a multiplex comparative threshold cycle method was employed as described previously (Wlodek *et al.*, 2005). 18s values were not different between treatments.

Fixed mammary tissue was processed into paraffin blocks, sectioned at 5 μ m and stained with haematoxylin and eosin (n = 4 - 5 per group). Five sections per sample were analyzed for alveolar area and number using ImagePro Software (Medai Cybernetics; Warrendale, PA, United States of America) (Wlodek *et al.*, 2003).

PTHrP, corticosterone, calcium and electrolyte measurements

Plasma, milk and mammary tissue concentrations of PTHrP were quantified by a N-terminal radioimmunoassay with a minimum detection limit of 2 pmol/l, and intra- and inter-assay

coefficients of variation of 4.8% and 13.6% respectively (Wlodek *et al.*, 1995). Plasma corticosterone was measured by enzyme immunoassay validated for direct measurements in diluted plasma following the manufacturer's protocol (Cayman Chemical; Ann Arbor, MI, United States of America) with a minimum detection limit of 30 pg/ml, and intra- and inter-assay coefficients of variation of 7.4% and 7% respectively. Total calcium concentrations were determined using colorimetric spectrometry using the Synchron CX-5 Clinical System (Beckman Coulter; Lane Cove, NSW, Australia) and ionic calcium (active or free calcium; regulated by PTHrP), sodium and potassium concentrations were determined using ion selective electrodes correcting for pH (Ciba-Corning model 644; Cambridge, MA, United States of America) from milk as well as from pup and maternal plasma (Wlodek *et al.*, 2000; Wlodek *et al.*, 2009). Total calcium concentration in the pup body was determined after ashing using the CX-5 Analyser (Wlodek *et al.*, 2003; O'Dowd *et al.*, 2008). Total protein and lactose concentrations were analysed as described previously (O'Dowd *et al.*, 2008).

Fatty acid analysis

Total fatty acid composition of the milk was determined by the direct trans-esterification method of Lepage and Roy (Lepage & Roy, 1986). Briefly, 50 to 100 μ L of milk was placed into a screw-capped Teflon-lined tube containing C23:0 as an internal standard. After the 1-hour trans-esterification procedure and recovery of the fatty acid methyl esters (FAMES) in the benzene phase, the FAMES were analyzed by capillary gas liquid chromatography. FAMES were then separated and measured on a Shimadzu (17A) gas chromatograph with flame ionization detection. A 50 mm $\times$ 0.25 mm BPX-70 fused silica capillary column (SGE Scientific; Ringwood, VIC, Australia) with a film thickness of 0.25 μ m was used in conjunction with a Shimadzu on-column auto-injector. Ultrahigh purity hydrogen was used as a carrier gas at a flow rate of 2 mL/min. A temperature gradient program was used with an initial temperature of 170°C, increasing at 3°C/min to 218°C. Identification of the FAMES was made by comparison with the retention times of chromatography reference standard mixtures (Nu-Chek Prep; Elysian, MN, United States of America) (Weisinger *et al.*, 1999).

Plasma leptin analysis

Leptin concentrations were determined from the developmental timeline study (E20, PN1, PN7 and PN35) and cross-foster study (PN7) from maternal and pup plasma, amniotic fluid (E20) and maternal milk (cross-foster study; PN7) using an enzyme-linked immunosorbent assay (ELISA) (R&D Systems; Minneapolis, MN, United States of America) as described previously (Romano *et al.*, 2015;

Tran *et al.*, 2015) with a minimum detection limit of 22 pg/ml, and intra- and inter-assay coefficients of variation of 3.8% and 5.8% respectively.

Statistical analysis

For the placental genes, a two-way ANOVA was conducted to determine differences between Treatment and Sex for each placental region (labyrinth and junctional zone). For amniotic and offspring leptin concentrations (PN1, PN7, and PN35) a two-way ANOVA was performed to identify if there were changes across Treatment groups and between Sexes. A Student's t-test was used if an interaction existed in the two-way ANOVA and to identify changes in body and placental weights, as well as maternal and fetal (E20) leptin concentrations.

For the cross-fostering groups, data were analyzed with a two-way ANOVA (Pup and Mother) that provided the main effect for statistical differences. If an interaction was present in the two-way ANOVA, the data was split to determine where the difference existed using a Student's t-test. ANOVA statistical analysis was performed using SPSS Statistics 22 (IBM; St Leonards, NSW, Australia) and Student's t-tests were performed using Excel (Microsoft; North Ryde, NSW, Australia). All data are presented as mean $\pm$ SEM and a $P < 0.05$ was assessed as being statistically significant.

Results

Study 1 - developmental timeline

Body and organ weights and leptin concentrations

There were no differences between treatment groups in maternal body weight at any developmental ages (data not shown). Mothers who underwent uteroplacental insufficiency surgery had lighter fetuses (E20 males 1.78 ± 0.05 g vs. 1.40 ± 0.06 g and females 1.73 ± 0.03 g vs. 1.40 ± 0.03 g, respectively for Control and Restricted; $P < 0.0001$, Student's t-test) and gave birth to smaller pups (PN1 males 4.29 ± 0.07 g vs. 3.45 ± 0.11 g and females 4.06 ± 0.05 g vs. 3.47 ± 0.12 g, respectively for Control and Restricted; $P < 0.0004$, Student's t-test) who remained smaller than Controls at all ages (PN35 males 78.32 ± 1.88 g vs. 68.63 ± 2.99 g and females 69.13 ± 1.92 g vs. 63.35 ± 2.46 g, respectively for Control and Restricted; $P < 0.034$, Student's t-test). Despite no changes in placental

weight (data not shown), fetal-placental ratio was reduced in Restricted fetuses (male 5.87 ± 0.15 vs. 4.71 ± 0.20 and female 5.76 ± 0.14 vs. 4.52 ± 0.10 , respectively for Control and Restricted; $P = 0.001$, Student's t-test). Mothers that underwent uteroplacental insufficiency surgery (Restricted) had no changes in plasma leptin concentrations at E20 (Figure 1A), increased plasma leptin concentrations at PN1 and PN7 (Figure 1B, $P < 0.014$, Student's t-test) but were not different at PN35 (Figure 1D) compared to sham operated (Control) mothers. Uteroplacental insufficiency reduced fetal plasma leptin concentrations (Figure 1A; $P = 0.045$, Student's t-test) and postnatal plasma leptin concentrations at all ages (except PN35 males) (Figure 1B – 1D; $P < 0.0001$, two-way ANOVA main effect (PN1 and PN7) and $P = 0.0045$ Student's t-test (PN35)). Control females had elevated plasma leptin concentrations at PN35 compared to Control males (Figure 1D; $P = 0.011$, Student's t-test). Despite the reductions in fetal leptin, amniotic fluid leptin concentrations were unaltered (Figure 1A).

Placental leptin transporter and signalling expression

Treatment: Uteroplacental insufficiency reduced *ObR* expression in the junctional zone and tended to reduce labyrinth *ObR* expression, however this did not reach statistical significance ($P = 0.057$, two-way ANOVA), in both males and females (Figure 2A). *Megalin* mRNA was increased in the placentae of Restricted fetuses in the labyrinth and was reduced in the junctional zone in Restricted females (Figure 2B; $P = 0.044$, Student's t-test). In the labyrinth of females, *megalin* mRNA expression was higher compared to males (Figure 2B). Megalin protein expression in the labyrinth was increased in females following uteroplacental insufficiency (Figure 2C; $P = 0.004$, Student's t-test), but not in males. Control females had lower megalin protein expression than Control males (Figure 2C; $P = 0.039$, Student's t-test). The molecular weight of megalin we observed is similar to those reported in several studies (Lebeau *et al.*, 2001; Zou *et al.*, 2004; Briffa *et al.*, 2015a) including in placental BeWo cells (Akour *et al.*, 2015).

Uteroplacental insufficiency increased junctional zone *leptin* expression in both male and female fetuses (Table 1). Downstream signalling mediators of ObR and megalin were altered in the labyrinth and junctional zone in response to uteroplacental insufficiency (see Table 1). Specifically, uteroplacental insufficiency alters *JAK2*, *STAT3*, *STAT5a*, *AMPK α* and *PI3K* (Restricted females only) (Table 1). Whereas in the junctional zone, following uteroplacental insufficiency, there was a reduction in *SOCS3* and increase in *AMPK α* in Restricted males and females (Table 1). In the junctional zone of females, *STAT5a*, *PI3K*, *Akt3* and *AMPK β* mRNA expression was higher compared to males (Table 1). As shown in Table 1, no treatment effect was observed in the junctional zone

expression of *JAK2*, *STAT3*, *STAT5a*, *PI3K*, *Akt3*, *mTOR*, and *AMPK β* or in the labyrinth expression of *SOCS3*, *Akt3*, *mTOR* and *AMPK β* .

Study 2 - cross-fostering

Body weight

We have previously demonstrated that uteroplacental insufficiency reduces litter size (Wlodek *et al.*, 2007; O'Dowd *et al.*, 2008). Consistent with this, cross-fostering litter size was reduced in mothers suckled by Restricted pups at PN6 (Table 2). Restricted pups had reduced body weight at PN1 (Table 2). Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) increased their body weight compared to Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) after PN1 in males and after PN10 in females (Table 2). Male and female Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) remained smaller than Control pups suckling sham operated (Control) mothers (*Control-on-Control*) throughout lactation (Table 2). Cross-fostering a Control pup onto a uteroplacental insufficiency surgery (Restricted) mother (*Control-on-Restricted*) reduced postnatal body weight after PN1 in males and after PN10 in female offspring compared to Control pups suckling sham operated (Control) mothers (*Control-on-Control*). Table 2 reports pup growth from birth to weaning.

Mammary structure and maternal plasma analysis

Cross-fostering did not alter maternal body weight at PN6 (Table 3). Despite no changes in alveolar number (data not shown), mammary alveolar area and absolute mammary weight were reduced in mothers suckled by Restricted pups (Figures 3A and 3B). Mammary β -casein mRNA expression was reduced in uteroplacental insufficiency surgery (Restricted) mothers and in mothers suckled by Restricted pups (Table 3). There were no changes in mammary α -lactalbumin and PTHrP mRNA expression (Table 3). Mammary PTHrP protein was reduced in mothers suckled by Restricted pups (Figure 3C); however no changes were observed in maternal plasma and milk PTHrP concentrations (Table 3). Despite a significant interaction in maternal corticosterone concentration (Table 3), post-hoc analysis did not identify any significant differences, which may be due to the natural variability in corticosterone concentrations.

Pup plasma analysis and milk consumption

Milk ionic calcium concentrations were increased in Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) compared to Control pups suckling sham operated (Control) mothers (*Control-on-Control*) as well as Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) (Table 3; $P = 0.044$ and $P = 0.005$ respectively, Student's t-test). Milk total calcium concentrations were reduced in mothers suckled by Restricted pups (Table 3). No changes were observed in milk Na^+/K^+ ratio, total protein and lactose across pups or mothers (Table 3). Pup plasma PTHrP concentrations were reduced in uteroplacental insufficiency surgery (Restricted) mothers (Table 3), whereas pup body total calcium (Table 3) and ionic calcium (Figure 3D) were reduced in Restricted pups. Milk intake in both males and females was reduced in Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) compared to both Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) and Control pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Control-on-Restricted*) (Figures 3E and 3F; $P < 0.013$, Student's t-test).

Mothers suckled by Restricted pups had increased plasma leptin concentrations at PN7 (Figure 4A). However, this increase in maternal plasma leptin concentrations did not alter milk leptin concentrations (Figure 4B). Pup plasma leptin concentrations were reduced in Restricted females suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) compared to Control females suckling uteroplacental insufficiency surgery mothers (*Control-on-Restricted*) and Restricted females suckling sham operated mothers (*Restricted-on-Control*; Figure 4D; $P < 0.011$, Student's t-test). A similar trend was also observed in male plasma leptin concentrations when we performed subsequent analysis (Figure 4C), however this interaction did not reach statistical significance ($p = 0.077$, two-way ANOVA).

Milk fatty acid composition

n-6 omega fatty acids were increased in the stomach contents of pups suckling uteroplacental insufficiency surgery (Restricted) mothers and in Restricted pups (Table 4). Stomach contents of n-3 fatty acids were increased in Restricted pups (Table 4). The n-3:n-6 ratio tended to show an

interaction (Table 4; $P = 0.057$, two-way ANOVA), however it did not reach statistical significance. Total long chain polyunsaturated fatty acids (LC-PUFA) and total long chain monounsaturated fatty acids (LC-MUFA) were increased in the stomach contents of Restricted pups, with total LC-PUFA also increased in pups suckling uteroplacental insufficiency surgery (Restricted) mothers (Table 4). No changes were observed in medium chain saturated fatty acids (Table 4). Long chain saturated fatty acids were reduced in Restricted pups and in pups suckling uteroplacental insufficiency surgery (Restricted) mothers (Table 4). Table 4 presents the cumulative total percentage of fatty acids in the stomach contents. The entire list of fatty acids analysed from the stomach contents are reported in Supplementary Table S1.

Discussion

This study has demonstrated that uteroplacental insufficiency in rats reduces pup plasma leptin concentrations, similar to what occurs following human uteroplacental insufficiency (Koklu *et al.*, 2007; Nezar *et al.*, 2009). Furthermore, this study has also demonstrated sex-specific alterations in placental leptin transporter expression and their downstream signalling pathways following uteroplacental insufficiency, which may impact on leptin transport. This suggests that sex-specific programmed disease risks in pups born small may in part be attributed to changes in the placental leptin transportation and signalling. We have previously reported that uteroplacental insufficiency reduces birth weight and the growth trajectory in both male and female pups (O'Dowd *et al.*, 2008). This study demonstrates that improving the lactational environment of these Restricted pups, by cross-fostering them onto a sham operated (Control) mother, restores plasma leptin concentrations and results in 'catch-up' growth, presumably via increased milk intake and nutrient delivery. An important finding of this study is that the pup plays an important role in modulating mammary development and milk fatty acid composition, which may prevent the organ deficits and disease outcomes in Restricted offspring suckling a sham operated (Control) mother (*Restricted-on-Control*) (Wlodek *et al.*, 2007; Moritz *et al.*, 2009).

Fetal plasma leptin concentrations and placental leptin transporter expression

Leptin transfer from the maternal to fetal circulatory systems is mediated by the placenta (Smith & Waddell, 2003). Currently it remains unknown what proportion of maternally derived leptin is transported to the fetus and the leptin transporter which is responsible. Despite no changes in

maternal plasma and amniotic leptin concentrations at E20 as well as the increased junctional zone *leptin* mRNA expression, growth restricted fetuses have reduced plasma leptin concentrations. This increased in leptin in the junctional zone (the hormone producing region of the placenta) suggests the placenta may be increasing leptin production, however previous rodent studies have demonstrated that placentally derived leptin is not a major source of leptin in the rat (Kawai *et al.*, 1997), so the implications this upregulation has may not be as effective in increasing fetal leptin. An important limitation of this study is that plasma from male and female fetuses were pooled at E20, which may obscure any sex-specific differences at this age. Interestingly, megalin protein expression was only increased in the labyrinth of Restricted females, despite both males and females having increased *megalyn* mRNA, which likely suggests alterations in mRNA translation and/or protein degradation in Restricted males. This may suggest that the mechanisms regulating leptin concentrations in the fetus are sex-specific, whereby Restricted females may attenuate the reduced transfer of leptin from the maternal interface by increasing leptin transport across the placenta via megalin. As Restricted males have no changes in placental cell surface availability of megalin, it is possible that their reduced fetal plasma leptin concentrations may be due to reduced fetal leptin production and/or reduced fetal adipocyte mass. However, further research is required to elucidate the plasma leptin concentrations in male and female growth restricted fetuses, and to identify the exact mechanism that may modulate any sex-specific alterations in fetal leptin concentrations.

A shortcoming of this study is that we were unable to quantify labyrinth ObR expression with Western blotting. As ObR has a large number of glycosylation sites that affects its size (Kamikubo *et al.*, 2008), its molecular weight appears to be tissue specific (Guerra *et al.*, 2007; Aquila *et al.*, 2008), and that different physiological states (including pregnancy) can affect its size (Lammert *et al.*, 2002) it limits the identification of the correct long (ObRb) and short (ObRa) isoforms. As there are several different isoforms of ObR (a – f) it is important for future studies to characterise their expression separately as they all have different physiological functions and roles. Specifically both the long (ObRb) and one of the short (ObRa) isoforms are responsible for transcellular leptin transportation (Frühbeck, 2006), whereas the soluble isoform (ObRe) is responsible for maintaining elevated maternal leptin concentrations during gestation by reducing leptin clearance (Attig *et al.*, 2011; Briffa *et al.*, 2015b). However only the long isoform (ObRb) has a transmembrane domain that is capable of activating signal transduction pathways (Bjørbaek *et al.*, 1997). Importantly previous studies have demonstrated that these three isoform (ObRa, b and e) are dysregulated in

compromised pregnancies (such as maternal glucocorticoid administration) (Smith & Waddell, 2002, 2003).

Only one study to date has investigated changes in amniotic leptin concentrations in growth restricted humans, where it is reduced in small for gestational age babies (Aydin *et al.*, 2014). This is in contrast to our finding, where we report no changes in amniotic leptin concentrations. These differences may be due to the study including babies that were born below the third percentile, identifying that these babies were severely growth restricted, whereas our rats were 15-20% lighter. Leptin clearly activates a number of signalling pathways in the placenta, which have previously been linked to trophoblast function. Specifically, STAT3 activity has been correlated with trophoblast invasiveness (Maymó *et al.*, 2011) and PI3K has been associated with trophoblast invasive differentiation in early pregnancy (Pérez-Pérez *et al.*, 2008). In this study, placentae associated with Restricted fetuses have increases in labyrinth *JAK2*, *STAT3* and *STAT5a* mRNA, which may suggest that the placenta is activating this signalling cascade to maintain normal placental growth in an adverse *in utero* environment. However, the effect these signalling pathways have on placental function in late gestation remains unknown and further research is required to identify if these gene changes translate to alterations in total and phosphorylated protein expression. As changes in *JAK/STAT* mRNA occur independently of changes in *ObR* mRNA and the *PI3K* pathway appears to be largely unaffected in response to uteroplacental insufficiency it suggests that other signalling cascades, which also regulate the expression of these targets may be dysregulated such as the Forkhead box O that also regulates cell growth, proliferation and differentiation. Despite increases in plasma leptin concentrations at PN1 and PN7 in uteroplacental insufficiency surgery (Restricted) mothers, plasma leptin concentrations remained lower in Restricted pups until weaning (females). This suggests that there may be alterations in pup leptin production and/or milk leptin absorption, which may further adversely impact on pup growth and development postnatally. However, we cannot at this time discount if the Restricted pups just have reduced plasma leptin concentrations or a delay in the postnatal plasma leptin surge, similar to what is observed following maternal protein restriction (Delahaye *et al.*, 2008), which requires future investigation.

Cross-fostering effects on mammary morphology, milk content and leptin concentrations

A novel finding of this study is that pups can influence maternal physiology. It is important to note that by cross-fostering Restricted offspring onto a sham operated (Control) mother we are

reducing the number of pups the mother has to feed (by approximately 50%). It is possible that this reduction in litter size may confound the interpretation of the findings, however the reduction in litter size is a direct consequence of the uteroplacental insufficiency surgery, thus we believe we have adequately accounted for this in our statistical approach. Nevertheless, in both sham operated (Control) and uteroplacental insufficiency surgery (Restricted) mothers suckled by Restricted pups, we characterized a reduction in mammary alveolar area, relative mammary weight and PTHrP protein. Reductions in maternal PTHrP protein would likely reduce pup plasma PTHrP; however PTHrP concentrations in the pups were modulated by the mother, such that pups suckling uteroplacental insufficiency surgery (Restricted) mothers had reduced PTHrP concentrations. Despite pup PTHrP being modulated by the mother, Restricted pups had reduced plasma calcium concentrations and total body calcium, which are likely due to PTHrPs influence on calcium transport from the maternal blood into milk. This finding strongly suggests that the phenotype and impairment in pup growth is not driven solely by the mother or the pup, but by both. One possible mechanism by which the pup can influence maternal milk production is through the feedback inhibitor of lactation (FIL) (Wilde *et al.*, 1998). Milk removal from the alveoli drives milk production with an increased suckling volume reducing FIL expression, ultimately increasing milk production (Wilde *et al.*, 1998). Interestingly, despite the Restricted pups reducing maternal alveolar area, pup milk intake was only reduced in Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*). The lower amount of milk removed by Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) would leave some milk in the alveoli increasing FIL expression and slowing milk production. Thus uteroplacental insufficiency surgery (Restricted) mothers may have altered milk production; however Control pups suckling a uteroplacental insufficiency surgery (Restricted) mother (*Control-on-Restricted*) are able to remove a greater amount of milk from the mammary gland due to their large size normalizing their milk intake and FIL expression and/or activity. An interesting finding is that the pup also influences maternal plasma leptin concentrations, with mothers suckled by Restricted pups having increased plasma leptin concentrations. These data suggest that, despite no changes in maternal body weight with cross-fostering, the increased maternal plasma leptin concentrations may be due to the pups influence on maternal adipose tissue deposition, maternal adipocyte hypertrophy, and/or maternal adipose leptin production. However no studies to date have investigated maternal adipocyte morphology and adipose leptin secretion in uteroplacental insufficiency surgery (Restricted) mothers due to uteroplacental insufficiency. Critically, pup plasma leptin concentrations were restored in Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*), which may partially be attributable to their increased milk consumption

compared to Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*).

Cross-fostering effects of milk fatty acids

Fatty acid analysis highlighted that the pups regulate fatty acid composition in the maternal milk. Specifically, Restricted pups resulted in increased LC-PUFA and LC-MUFA content, and a reduction in long chain saturated fatty acids in the maternal milk. Additionally, LC-PUFA was increased and long chain saturated fatty acids were reduced in pups suckling uteroplacental insufficiency surgery (Restricted) mothers. These increases in LC-MUFA and LC-PUFA composition would increase the thermogenic capacity in the pup (preventing obesity) and improve pup physiological and metabolic function during critical periods of development, which is protective against the development of metabolic disease (Mennitti *et al.*, 2015). Additionally, the reduction in saturated fatty acids during development would be protective against the development of obesity, diabetes and cardiovascular disease (Mennitti *et al.*, 2015). These improvements in fatty acid composition are modulated by the pups, suggesting that the pups are somehow regulating maternal milk consumption to improve their growth and development. Despite the benefits increased LC-MUFAs and LC-PUFAs as well as reduced saturated fatty acids have on cardiometabolic health, the Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*) go on to develop metabolic dysfunction, whereas the Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) pups are protected (Siebel *et al.*, 2008). These differences in disease outcomes may be due to the increased milk consumption in the Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) pups, which would further enhance the delivery of these beneficial fatty acids improving pup growth and development (Wlodek *et al.*, 2007; Moritz *et al.*, 2009) and protect them against adulthood diseases. Despite increases in n-3 and n-6 fatty acids in Restricted pups and in pups suckling uteroplacental insufficiency surgery (Restricted) mothers (*Restricted-on-Restricted*; n-3 only), the n-3:n-6 ratio was unaffected suggesting omega fatty acids would not adversely impact on pup growth and development (Morris, 2007). Previous research has demonstrated that mothers fed a high n-3 fatty acid diet results in reduced pup plasma leptin concentrations, despite no changes in maternal milk leptin concentrations (Korotkova *et al.*, 2002). Studies in dexamethasone treated WKY rats during pregnancy have also demonstrated that maternal diet high in n-3 during lactation reduces offspring blood pressure (Wyrwoll *et al.*, 2006). Therefore, a maternal diet high in n-3 fatty acids and/or altered n-3 fatty acid composition in the maternal milk may impact on pup plasma leptin concentrations and prevent cardiovascular disease.

The mothers in the current study were fed the same chow during gestation and lactation indicating that the diet is not affecting fetal and pup leptin concentrations. This finding suggests that the increased n-3 content in the milk of dams suckled by Restricted pups (both sham operated (*Restricted-on-Control*) and uteroplacental insufficiency surgery (*Restricted-on-Restricted*) mothers) may impact on pup plasma leptin concentrations. However the increased milk consumption in Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*), despite increased milk n-3, is likely responsible for the restoration of plasma leptin concentrations and improved cardiovascular function in these pups (Moritz *et al.*, 2009; Tare *et al.*, 2012; Wadley *et al.*, 2013). It is also important to consider that although these changes in fatty acid intake during lactation may be beneficial on pup health and development during the early postnatal period, an increased consumption of many of these fatty acids in adulthood may increase their disease risk.

Conclusion

In summary, this study demonstrates that perinatal growth restriction reduces pup plasma leptin concentrations that are restored by cross-fostering Restricted pups onto a mother with normal lactation (sham operated), which may be attributable to increased milk consumption and nutritional intake. We identified that growth restriction alters placental leptin transporter expression and signalling in a region and sex-specific manner. This study demonstrates that Restricted pups enhance milk fatty acid composition, which is likely in an attempt to enhance pup growth and organ development. However, despite the enhanced milk fatty acid composition, the limited ability of the uteroplacental insufficiency surgery (Restricted) mothers to supply adequate milk is detrimental on the Restricted pups (*Restricted-on-Restricted*) development and adulthood health. Whereas the increased nutrient delivery, milk intake and plasma leptin concentrations in Restricted pups suckling sham operated (Control) mothers (*Restricted-on-Control*) would prevent the deleterious changes reported in the Restricted pups suckling uteroplacental insufficiency surgery mothers (*Restricted-on-Restricted*). Thus, further investigation into the role leptin plays in placental function, organogenesis and the organ-specific signalling targets that leptin activates is required. This study highlights an important window of intervention in rodents to enhance offspring growth and development by enhancing leptin delivery to offspring during lactation, which may prevent the deleterious adult health conditions in offspring born growth restricted.

5. References

- Ahima RS, Prabakaran D & Flier JS. (1998). Postnatal leptin surge and regulation of circadian rhythm of leptin by feeding. Implications for energy homeostasis and neuroendocrine function. *J Clin Invest* **101**, 1020 - 1027.
- Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E & Flier JS. (1996). Role of leptin in the neuroendocrine response to fasting. *Nature* **382**, 250 - 252.
- Akour AA, Kennedy MJ & Gerk PM. (2015). The Role of Megalin in the Transport of Gentamicin Across BeWo Cells, an In Vitro Model of the Human Placenta. *AAPS J* **17**, 1193-1199.
- Aquila S, Rago V, Guido C, Casaburi I, Zupo S & Carpino A. (2008). Leptin and leptin receptor in pig spermatozoa: evidence of their involvement in sperm capacitation and survival. *Reproduction* **136**, 23-32.
- Attig L, Larcher T, Gertler A, Abdennebi-Najar L & Djiane J. (2011). Postnatal leptin is necessary for maturation of numerous organs in newborn rats. *Organogenesis* **7**, 88 - 94.
- Aydın Hİ, Demirkaya E, Karadeniz RS, Olgun A & Alpay F. (2014). Assessing leptin and soluble leptin receptor levels in full-term asymmetric small for gestational age and healthy neonates. *Turk J Pediatr* **56**, 250 - 258.
- Banks AS, Davis SM, Bates SH & Myers MGJ. (2000). Activation of downstream signals by the long form of the leptin receptor. *J Biol Chem* **275**, 14563 - 14572.
- Barker DJ. (2007). The origins of the developmental origins theory. *J Intern Med* **261**, 412 - 417.
- Barker DJ, Osmond C, Golding J, Kuh D & Wadsworth ME. (1989). Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ* **298**, 564 - 567.

- Bjørbaek C, Uotani S, da Silva B & Flier JS. (1997). Divergent signaling capacities of the long and short isoforms of the leptin recepto. *J Biol Chem* **272**, 32686 - 32695.
- Black MJ, Siebel AL, Gezmish O, Moritz KM & Wlodek ME. (2012). Normal lactational environment restores cardiomyocyte number after uteroplacental insufficiency: implications for the preterm neonate. *Am J Physiol Regul Integr Comp Physiol* **302**, R1101 - R1110.
- Briffa JF, Grinfeld E, Mathai ML, Poronnik P, McAinch AJ & Hryciw DH. (2015a). Acute leptin exposure reduces megalin expression and upregulates TGF β 1 in cultured renal proximal tubule cells. *Mol Cell Endocrinol* **401**, 25 - 34.
- Briffa JF, Grinfeld E, McAinch AJ, Poronnik P & Hryciw DH. (2014). Short term exposure to elevated levels of leptin reduces proximal tubule cell metabolic activity. *Mol Cell Endocrinol* **382**, 38 - 45.
- Briffa JF, McAinch AJ, Romano T, Wlodek ME & Hryciw DH. (2015b). Leptin in pregnancy and development: a contributor to adulthood disease? *Am J Physiol Endocrinol Metab* **308**, E335 - E350.
- Cuffe JS, O'Sullivan L, Simmons DG, Anderson ST & Moritz KM. (2012). Maternal corticosterone exposure in the mouse has sex-specific effects on placental growth and mRNA expression. *Endocrinology* **153**, 5500 - 5511.
- Cuffe JS, Walton SL, Singh RR, Spiers JG, Bielefeldt-Ohmann H, Wilkinson L, Little MH & Moritz KM. (2014). Mid- to late term hypoxia in the mouse alters placental morphology, glucocorticoid regulatory pathways and nutrient transporters in a sex-specific manner. *J Physiol* **592**, 3127-3141.
- Delahaye F, Breton C, Risold PY, Enache M, Dutriez-Casteloot I, Laborie C, Lesage J & Vieau D. (2008). Maternal perinatal undernutrition drastically reduces postnatal leptin surge and affects the development of arcuate nucleus proopiomelanocortin neurons in neonatal male rat pups. *Endocrinology* **149**, 470 - 475.

- Dickinson H, Moss TJ, Gatford KL, Moritz KM, Akison L, Fullston T, Hryciw DH, Maloney CA, Morris MJ, Wooldridge AL, Schjenken JE, Robertson SA, Waddell BJ, Mark PJ, Wyrwoll CS, Ellery SJ, Thornburg KL, Muhlhausler BS & Morrison JL. (2016). A review of fundamental principles for animal models of DOHaD research: an Australian perspective. *J Dev Orig Health Dis* **7**, 449 - 472.
- Doneray H, Orbak Z & Yildiz L. (2009). The relationship between breast milk leptin and neonatal weight gain. *Acta Paediatr* **98**, 643 - 647.
- Dundar NO, Anal O, Dundar B, Ozkan H, Caliskan S & Büyükgebiz A. (2005). Longitudinal investigation of the relationship between breast milk leptin levels and growth in breast-fed infants. *J Pediatr Endocrinol Metab* **18**, 181 - 187.
- Eriksson J, Forsén T, Tuomilehto J, Osmond C & Barker D. (2000). Fetal and childhood growth and hypertension in adult life. *Hypertension* **36**, 790 - 794.
- Frühbeck G. (2006). Intracellular signalling pathways activated by leptin. *Biochem J* **393**, 7 - 20.
- Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U & Forbes JM. (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. *Sci Rep*, doi: 10.1038/srep26428.
- Gluckman PD, Hanson MA, Cooper C & Thornburg KL. (2008). Effect of in utero and early-life conditions on adult health and disease. *N Engl J Med* **359**, 61 - 73.
- Guerra B, Santana A, Fuentes T, Delgado-Guerra S, Cabrera-Socorro A, Dorado C & Calbet JA. (2007). Leptin receptors in human skeletal muscle. *J Appl Physiol* **102**, 1786-1792.
- Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama JJ & Gejyo F. (2004). Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. *Endocrinology* **145**, 3935 - 3940.

- Hughson M, Farris ABr, Douglas-Denton R, Hoy WE & Bertram JF. (2003). Glomerular number and size in autopsy kidneys: the relationship to birth weight. *Kidney Int* **63**, 2113 - 2122.
- Kamikubo Y, Dellas C, Loskutoff DJ, Quigley JP & Ruggeri ZM. (2008). Contribution of leptin receptor N-linked glycans to leptin binding. *Biochem J* **410**, 595-604.
- Kawai M, Yamaguchi M, Murakami T, Shima K, Murata Y & Kishi K. (1997). The placenta is not the main source of leptin production in pregnant rat: gestational profile of leptin in plasma and adipose tissues. *Biochem Biophys Res Commun* **240**, 798 - 802.
- Kim J, Kundu M, Viollet B & Guan KL. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* **13**, 132 - 141.
- Koklu E, Ozturk MA, Kurtoglu S, Akcokus M, Yikilmaz A & Gunes T. (2007). Aortic intima-media thickness, serum IGF-I, IGFBP-3, and leptin levels in intrauterine growth-restricted newborns of healthy mothers. *Pediatr Res* **62**, 704 - 709.
- Korotkova M, Gabrielsson B, Lönn M, Hanson LA & Strandvik B. (2002). Leptin levels in rat offspring are modified by the ratio of linoleic to alpha-linolenic acid in the maternal diet. *J Lipid Res* **43**, 1743 - 1749.
- Lammert A, Brockmann G, Renne U, Kiess W, Böttner A, Thiery J & Kratzsch J. (2002). Different isoforms of the soluble leptin receptor in non-pregnant and pregnant mice. *Biochem Biophys Res Commun* **298**, 798-804.
- Landt M, Ludbrook PA & Billadello JJ. (2003). Role of protein binding in renal elimination of leptin. *Clin Endocrinol (Oxf)* **59**, 44 - 48.
- Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O & Beauwens R. (2001). Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. *Kidney Int* **60**, 1332-1342.

Lepage G & Roy CC. (1986). Direct transesterification of all lipid classes in a one-step reaction. *J Lipid Res* **27**, 114 - 120.

Lucas A, Fewtrell MS, Davies PS, Bishop NJ, Clough H & Cole TJ. (1997). Breastfeeding and catch-up growth in infants born small for gestational age. *Acta Paediatr* **86**, 564 - 569.

Maymó JL, Pérez Pérez A, Gambino Y, Calvo JC, Sánchez-Margalet V & Varone CL. (2011). Review: Leptin gene expression in the placenta--regulation of a key hormone in trophoblast proliferation and survival. *Placenta* **32**, S146 - S153.

McMillen IC & Robinson JS. (2005). Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Rev* **85**, 571 - 633.

Mennitti LV, Oliveira JL, Morais CA, Estadella D, Oyama LM, Oller do Nascimento CM & Pisani LP. (2015). Type of fatty acids in maternal diets during pregnancy and/or lactation and metabolic consequences of the offspring. *J Nutr Biochem* **26**, 99 - 111.

Moritz KM, Mazzuca MQ, Siebel AL, Mibus A, Arena D, Tare M, Owens JA & Wlodek ME. (2009). Uteroplacental insufficiency causes a nephron deficit, modest renal insufficiency but no hypertension with ageing in female rats. *J Physiol (Lond)* **587**, 2635 - 2646.

Morris DH. (2007). *Flax – A Health and Nutrition Primer*. Flax Council of Canada, Winnipeg, Canada.

Morton JS, Cooke CL & Davidge ST. (2016). In utero origins of hypertension: mechanisms and targets for therapy. *Physiol Rev* **96**, 549 - 603.

Nezar MA, el-Baky AM, Soliman OA, Abdel-Hady HA, Hammad AM & Al-Haggar MS. (2009). Endothelin-1 and leptin as markers of intrauterine growth restriction. *Indian J Pediatr* **76**, 485 - 488.

Nüsken KD, Schneider H, Plank C, Trollmann R, Nüsken E, Rascher W & Dötsch J. (2011). Fetal programming of gene expression in growth-restricted rats depends on the cause of low birth weight. *Endocrinology* **152**, 1327 - 1335.

- O'Dowd R, Kent JC, Moseley JM & Wlodek ME. (2008). Effects of uteroplacental insufficiency and reducing litter size on maternal mammary function and postnatal offspring growth. *Am J Physiol Regul Integr Comp Physiol* **294**, R539 - R548.
- Parviainen VI, Joenväärä S, Tohmola N & Renkonen R. (2013). Label-free mass spectrometry proteome quantification of human embryonic kidney cells following 24 hours of sialic acid overproduction. *Proteome Science* **11**, 38.
- Pérez-Pérez A, Maymó J, Dueñas JL, Goberna R, Calvo JC, Varone C & Sánchez-Margalet V. (2008). Leptin prevents apoptosis of trophoblastic cells by activation of MAPK pathway. *Arch Biochem Biophys* **477**, 390 - 395.
- Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE & Stewart AF. (1996). Defining the roles of the parathyroid hormone-related protein in normal physiology. *Physiol Rev* **76**, 127 - 173.
- Romano T, Hryciw DH, Westcott KT & Wlodek ME. (2015). Puberty onset is delayed following uteroplacental insufficiency and occurs earlier with improved lactation and growth for pups born small. *Reprod Fertil Dev*, doi: 10.1071/RD15151.
- Rosario FJ, Jansson N, Kanai Y, Prasad PD, Powell TL & Jansson T. (2011). Maternal protein restriction in the rat inhibits placental insulin, mTOR, and STAT3 signaling and down-regulates placental amino acid transporters. *Endocrinology* **152**, 1119-1129.
- Siebel AL, Gallo LA, Guan TC, Owens JA & Wlodek ME. (2010). Cross-fostering and improved lactation ameliorates deficits in endocrine pancreatic morphology in growth-restricted adult male rat offspring. *J Dev Orig Health Dis* **1**, 234 - 244.
- Siebel AL, Mibus A, De Blasio MJ, Westcott KT, Morris MJ, Prior L, Owens JA & Wlodek ME. (2008). Improved lactational nutrition and postnatal growth ameliorates impairment of glucose tolerance by uteroplacental insufficiency in male rat offspring. *Endocrinology* **149**, 3067 - 3076.

- Smith JT & Waddell BJ. (2002). Leptin receptor expression in the rat placenta: changes in ob-ra, ob-rb, and ob-re with gestational age and suppression by glucocorticoids. *Biol Reprod* **67**, 1204 - 1210.
- Smith JT & Waddell BJ. (2003). Leptin distribution and metabolism in the pregnant rat: transplacental leptin passage increases in late gestation but is reduced by excess glucocorticoids. *Endocrinology* **144**, 3024 - 3030.
- Tare M, Parkington HC, Bubb KJ & Wlodek ME. (2012). Uteroplacental insufficiency and lactational environment separately influence arterial stiffness and vascular function in adult male rats. *Hypertension* **60**, 378 - 386.
- Tran M, Young ME, Jefferies AJ, Hryciw DH, Ward MM, Fletcher EL, Wlodek ME & Wadley GD. (2015). Uteroplacental insufficiency leads to hypertension, but not glucose intolerance or impaired skeletal muscle mitochondrial biogenesis, in 12-month-old rats. *Physiol Rep* **3**, e12556.
- Wadley GD, McConell GK, Goodman CA, Siebel AL, Westcott KT & Wlodek ME. (2013). Growth restriction in the rat alters expression of metabolic genes during postnatal cardiac development in a sex-specific manner. *Physiol Genomics* **45**, 99 - 105.
- Weisinger HS, Vingrys AJ, Bui BV & Sinclair AJ. (1999). Effects of dietary n-3 fatty acid deficiency and repletion in the guinea pig retina. *Invest Ophthalmol Vis Sci* **40**, 327 - 338.
- Wilde CJ, Addey CV, Bryson JM, Finch LM, Knight CH & Peaker M. (1998). Autocrine regulation of milk secretion. *Biochem Soc Symp* **63**, 81-90.
- Wlodek ME, Ceranic V, O'Dowd R, Westcott KT & Siebel AL. (2009). Maternal progesterone treatment rescues the mammary impairment following uteroplacental insufficiency and improves postnatal pup growth in the rat. *Reprod Sci* **16**, 380 - 390.
- Wlodek ME, Ho PW, Rice GE, Moseley JM, Martin TJ & Brennecke SP. (1995). Parathyroid hormone-related protein (PTHrP) concentrations in human amniotic fluid during gestation and at the time of labour. *Reprod Fertil Dev* **7**, 1509 - 1513.

Wlodek ME, Mibus A, Tan A, Siebel AL, Owens JA & Moritz KM. (2007). Normal lactational environment restores nephron endowment and prevents hypertension after placental restriction in the rat. *J Am Soc Nephrol* **18**, 1688 - 1696.

Wlodek ME, Westcott KT, Ho PW, Serruto A, Di Nicolantonio R, Farrugia W & Moseley JM. (2000). Reduced fetal, placental, and amniotic fluid PTHrP in the growth-restricted spontaneously hypertensive rat. *Am J Physiol Regul Integr Comp Physiol* **279**, R31 - R38.

Wlodek ME, Westcott KT, O'Dowd R, Serruto A, Wassef L, Moritz KM & Moseley JM. (2005). Uteroplacental restriction in the rat impairs fetal growth in association with alterations in placental growth factors including PTHrP. *Am J Physiol Regul Integr Comp Physiol* **288**, R1620 - R1627.

Wlodek ME, Westcott KT, Serruto A, O'Dowd R, Wassef L, Ho PW & Moseley JM. (2003). Impaired mammary function and parathyroid hormone-related protein during lactation in growth-restricted spontaneously hypertensive rats. *J Endocrinol* **178**, 233 - 245.

Wyrwoll CS, Mark PJ, Mori TA, Puddey IB & Waddell BJ. (2006). Prevention of programmed hyperleptinemia and hypertension by postnatal dietary omega-3 fatty acids. *Endocrinology* **147**, 599 - 606.

Zou Z, Chung B, Nguyen T, Mentone S, Thomson B & Biemesderfer D. (2004). Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. *J Biol Chem* **279**, 34302 - 34310.

Competing Interests

The authors declare no conflicts of interest.

Author Contributions

J.F.B., R.O., K.M.M., T.R., M.E.W. and D.H.H. designed the study. J.F.B. and R.O., with assistance from L.R.J. and T.R., performed all experiments. All authors participated in the interpretation of the results

and contributed to writing the manuscript. All authors approved the submission of this version to the Journal of Physiology.

Funding

This research was supported by the National Health and Medical Research Council (NHMRC) of Australia (M.E.W. 208948; M.E.W. and K.M. 400003), an Early Career Researcher (ECR) grant from the University of Melbourne (D.H.H.), and a La Trobe University Faculty of Health Sciences Research Grant Award (T.R.). J.F.B. holds a Elizabeth and Vernon Puzey Postdoctoral Fellowship at the University of Melbourne.

Acknowledgements

We thank Ursula Lorenc for her technical assistance and Professor Jane Moseley for her assistance in this project. We also thank Samantha van der Linde for her assistance with leptin ELISAs, Prof Andrew Sinclair for his assistance with the fatty acid analysis, Prof Kevin Nicholas for his assistance with mammary gland morphology. We also thank Dr Andrew Siebel, Mr Andrew Jefferies and Ms Kerry Westcott for their assistance with the animal work involved in this project.

Translational Perspective

Uteroplacental insufficiency reduces birth weight and adversely affects fetal organ development, increasing adult disease risk. Plasma leptin concentration peaks during the completion of organ development. Leptin is transferred to the fetus (via placenta) and to the pup (via lactating mammary gland). Mothers with growth restricted pups have compromised milk production and composition. Cross-fostering improves postnatal nutrition and restores the organ deficits associated with growth restriction. This study investigated the effect of uteroplacental insufficiency on pup plasma leptin concentrations and placental leptin transporters. We additionally examined if cross-fostering improves mammary development, milk composition and pup plasma leptin concentrations. Growth restricted fetuses had reduced plasma leptin concentrations that persisted throughout lactation, reduced placental leptin and sex-specific alterations in placental leptin transporters. Mothers suckled by Restricted pups have impaired mammary development, altered milk fatty acid composition and increased plasma leptin concentrations, which did not correlate to altered milk

leptin. Despite these changes, cross-fostering Restricted pups onto sham operated mothers improved postnatal growth, milk intake and plasma leptin concentrations compared to Restricted pups suckling uteroplacental insufficiency surgery mothers. Human studies are now necessary to ascertain whether mother's breastfeeding their growth restricted baby further compromises neonatal growth due to compromised mammary development and milk composition, and their baby consumes less milk. These data may provide evidence for supplementing the milk of mothers who have growth restricted or premature babies. However, further studies are required to determine if donated breast milk or infant formula (normal or specially designed) would be beneficial for infant growth and development.

Word Count - 250

Figure Legends

Figure 1. The effect fetal growth restriction has on plasma and amniotic leptin concentrations. Maternal and fetal plasma leptin concentrations and amniotic leptin concentrations at embryonic day 20 (E20; $n = 5-11$) (A), maternal and pup plasma leptin concentrations on postnatal day (PN) 1 (B; $n = 3-8$), PN7 (C; $n = 5-9$) and PN35 (D; $n = 4-9$). Maternal and fetal (E20) plasma was analysed with a Student's t-test determine differences between pups (Control vs. Restricted) and mothers (sham operated (Control) vs. uteroplacental insufficiency surgery (Restricted)) at each time point. Amniotic and offspring plasma was analysed with a two-way ANOVA to determine differences between Treatments and Sexes, with a Student's t-test if an interaction was present. Data are expressed as mean $\pm$ SEM, where ns is not significant. Significant differences between treatment groups are indicated by an asterisk ($*P < 0.05$) and differences between males and females are indicated by a hashtag ($\#P < 0.05$). Control fetuses denoted by white open bars; Restricted fetuses denoted by black closed bars.




Figure 2. The effect fetal growth restriction has on placental leptin transporter expression on embryonic day 20 (n = 7-8 per group, with n = 1 representing 1 pup from 1 litter). Placental gene expression of the leptin receptor (ObR; A) and gene (B) and protein (C) expression of megalin in male (left pane) and female (right pane) fetuses in the labyrinth (left graph) and junctional zone (right graph). Protein expression of interest were normalized relative to Stain-Free total protein (Parviainen *et al.*, 2013). Gene data were analysed with a two-way ANOVA to determine differences between Treatment and Sex for each placental region (labyrinth and junctional zone), with a Student's t-test used to identify where interactions lie. Data are expressed as mean $\pm$ SEM, where ns is not significant. Significant differences between treatment groups are indicated by an asterisk (* P < 0.05), differences between males and females are indicated by a hashtag (# P < 0.05), and differences across placenta regions are indicated with a double dagger (‡ P < 0.05). Control fetuses denoted by white open bars; Restricted fetuses denoted by black closed bars.




Figure 3. Cross-fostering effects on mammary structure, pup ionic calcium concentrations and milk consumption at postnatal day 6 (n = 6-10 dams or offspring litter averages per group). (A) Mammary alveolar area and relative mammary weight (B) was reduced in mothers suckled by Restricted pups. (C) Mammary PTHrP content was reduced in mothers suckled by Restricted pups, which coincided with the reduced pup plasma ionic calcium at postnatal day 6 (D). (E and F) Milk intake area between days 3 and 17 of lactation was reduced in Restricted pups suckling uteroplacental insufficiency surgery (Restricted) mothers compared to both Restricted pups suckled by sham operated (Control) mothers and Control pups suckled by uteroplacental insufficiency surgery (Restricted) mothers. Data are analysed with a two-way ANOVA reporting differences between Pup and Mother groups and are expressed as mean $\pm$ SEM, where ns is not significant. Control pups denoted by white open bars; Restricted pups denoted by black closed bars.




Figure 4. Cross-fostering effects on maternal, milk and pup leptin concentrations at postnatal day 7 (n = 4-8 dams or offspring litter averages per group). (A) Maternal plasma leptin concentrations were increased in uteroplacental insufficiency surgery (Restricted) mothers. (B) Despite no changes in milk leptin concentrations, plasma leptin concentrations tended to be reduced in Restricted males (C), and was reduced in Restricted females suckling uteroplacental insufficiency surgery (Restricted) mothers (D). Data are analysed with a two-way ANOVA reporting differences between Pup and Mother groups with a Student's t-test used to identify where interactions lie. Data are expressed as mean $\pm$ SEM, where ns is not significant. Control pups denoted by white open bars; Restricted pups denoted by black closed bars.




Table 1. Placental gene expression of downstream pathways activated by the leptin receptors ObR and megalin at embryonic day 20 (n = 7-8 per group, with n = 1 representing 1 pup from 1 litter). Data were analysed with a two-way ANOVA to determine the main differences between Treatments and Sexes, with a Student's t-test used to identify where interactions lie. Data presented as arbitrary units with the mean $\pm$ SEM, where ns is not significant. Significant differences between Control and Restricted pups are indicated by an asterisk (* $P < 0.05$).

		Male		Female		Two-way ANOVA		
		Control	Restricted	Control	Restricted	Sex	Treatment	Interaction
Leptin	Labyrinth	1.00 $\pm$ 0.38	0.62 $\pm$ 0.14	1.27 $\pm$ 0.55	0.84 $\pm$ 0.15	ns	ns	ns
	Junctional Zone	1.00 $\pm$ 0.19	1.58 $\pm$ 0.38	1.05 $\pm$ 0.21	3.23 $\pm$ 0.91	ns	$P = 0.008$	ns
<i>ObR Signalling</i>								
JAK2	Labyrinth	1.00 $\pm$ 0.19	1.41 $\pm$ 0.10	1.13 $\pm$ 0.09	1.29 $\pm$ 0.10	ns	$P = 0.007$	ns
	Junctional Zone	1.00 $\pm$ 0.07	0.97 $\pm$ 0.03	0.99 $\pm$ 0.06	0.79 $\pm$ 0.07	ns	ns	ns
STAT3	Labyrinth	1.00 $\pm$ 0.12	1.54 $\pm$ 0.11	1.12 $\pm$ 0.08	1.36 $\pm$ 0.13	ns	$P = 0.002$	ns
	Junctional Zone	1.00 $\pm$ 0.08	0.76 $\pm$ 0.05	0.96 $\pm$ 0.09	0.97 $\pm$ 0.09	ns	ns	ns
STAT5a	Labyrinth	1.00 $\pm$ 0.15	1.19 $\pm$ 0.07	0.76 $\pm$ 0.10	1.39 $\pm$ 0.19	ns	$P = 0.007$	ns
	Junctional Zone	1.00 $\pm$ 0.12	1.05 $\pm$ 0.18	1.30 $\pm$ 0.11	1.80 $\pm$ 0.34	$P = 0.027$	ns	ns
SOCS3	Labyrinth	1.00 $\pm$ 0.12	1.05 $\pm$ 0.12	1.26 $\pm$ 0.12	1.06 $\pm$ 0.11	ns	ns	ns
	Junctional Zone	1.00 $\pm$ 0.20	0.60 $\pm$ 0.03	1.13 $\pm$ 0.09	0.61 $\pm$ 0.09	ns	$P = 0.001$	ns
<i>Megalin Signalling</i>								
PI3K	Labyrinth	1.00 $\pm$ 0.17	0.91 $\pm$ 0.12	1.37 $\pm$ 0.12	0.66 $\pm$ 0.04*	ns	$P = 0.003$	$P = 0.018$
	Junctional Zone	1.00 $\pm$ 0.19	0.95 $\pm$ 0.15	1.13 $\pm$ 0.23	1.81 $\pm$ 0.19	$P = 0.014$	ns	ns
Akt3	Labyrinth	1.00 $\pm$ 0.10	1.34 $\pm$ 0.20	1.07 $\pm$ 0.13	1.24 $\pm$ 0.11	ns	ns	ns
	Junctional Zone	1.00 $\pm$ 0.08	1.05 $\pm$ 0.09	1.24 $\pm$ 0.08	1.21 $\pm$ 0.13	$P = 0.047$	ns	ns
mTOR	Labyrinth	1.00 $\pm$ 0.07	0.91 $\pm$ 0.09	1.03 $\pm$ 0.07	0.86 $\pm$ 0.08	ns	ns	ns
	Junctional Zone	1.00 $\pm$ 0.10	0.92 $\pm$ 0.07	0.96 $\pm$ 0.07	1.05 $\pm$ 0.10	ns	ns	ns
AMPK α	Labyrinth	1.00 $\pm$ 0.13	1.24 $\pm$ 0.06	1.02 $\pm$ 0.06	1.27 $\pm$ 0.13	ns	$P = 0.039$	ns
	Junctional Zone	1.00 $\pm$ 0.10	1.34 $\pm$ 0.05	1.22 $\pm$ 0.08	1.33 $\pm$ 0.06	ns	$P = 0.006$	ns
AMPK β	Labyrinth	1.00 $\pm$ 0.13	1.27 $\pm$ 0.10	1.29 $\pm$ 0.13	1.48 $\pm$ 0.21	ns	ns	ns
	Junctional Zone	1.00 $\pm$ 0.12	0.94 $\pm$ 0.04	1.43 $\pm$ 0.12	1.06 $\pm$ 0.14	$P = 0.023$	ns	ns

Table 2. Cross-fostered litter size at postnatal day (PN) 6 and body weight from birth (PN1) to weaning (PN35) (n = 12 – 18 litter averages per group). Data are analysed with a two-way ANOVA reporting differences between Pup and Mother groups with a Student's t-test used to identify where interactions lie. Data presented as the mean $\pm$ SEM, where ns is not significant. Significant differences between Control and Restricted pups on the same mother group are indicated by an asterisk (* $P < 0.05$) and differences between sham operated (Control) and uteroplacental insufficiency surgery (Restricted) mothers with the same pup group are indicated with a double dagger ($\ddagger P < 0.05$).

Pup -on- Mother		Control -on- Control	Control -on- Restricted	Restricted -on- Control	Restricted -on- Restricted	Two-way ANOVA		
						Pup	Mother	Interaction
Litter Size at PN6		8.9 $\pm$ 0.6	8.6 $\pm$ 0.8	4.3 $\pm$ 0.6	3.1 $\pm$ 0.2	$P = 0.0001$	ns	ns
Body Weight (g)								
PN1	Male	4.17 $\pm$ 0.12	4.13 $\pm$ 0.10	3.68 $\pm$ 0.13	3.56 $\pm$ 0.09	$P = 0.0001$	ns	ns
	Female	3.87 $\pm$ 0.12	3.98 $\pm$ 0.06	3.46 $\pm$ 0.10	3.39 $\pm$ 0.08	$P = 0.0001$	ns	ns
PN3	Male	5.62 $\pm$ 0.11	5.42 $\pm$ 0.15	4.73 $\pm$ 0.15	4.23 $\pm$ 0.23	$P = 0.0001$	$P = 0.040$	ns
	Female	5.38 $\pm$ 0.12	5.16 $\pm$ 0.20	4.59 $\pm$ 0.14	4.33 $\pm$ 0.18	$P = 0.0001$	ns	ns
PN6	Male	8.54 $\pm$ 0.21	8.30 $\pm$ 0.23	7.13 $\pm$ 0.22	6.39 $\pm$ 0.32	$P = 0.0001$	$P = 0.055$	ns
	Female	8.17 $\pm$ 0.21	7.91 $\pm$ 0.37	7.06 $\pm$ 0.31	6.76 $\pm$ 0.24	$P = 0.0001$	ns	ns
PN10	Male	14.6 $\pm$ 0.3	14.1 $\pm$ 0.4	12.4 $\pm$ 0.4	10.8 $\pm$ 0.7	$P = 0.0001$	$P = 0.045$	ns
	Female	14.2 $\pm$ 0.3	13.6 $\pm$ 0.6	12.2 $\pm$ 0.5	11.2 $\pm$ 0.6	$P = 0.0001$	ns	ns
PN14	Male	22.1 $\pm$ 0.5	21.2 $\pm$ 0.6	19.3 $\pm$ 0.6	16.2 $\pm$ 1.0	$P = 0.0001$	$P = 0.006$	ns
	Female	21.7 $\pm$ 0.4	20.6 $\pm$ 0.8	19.7 $\pm$ 0.8	17.1 $\pm$ 0.8	$P = 0.0001$	$P = 0.008$	ns
PN17	Male	27.4 $\pm$ 0.6	26.3 $\pm$ 0.6	24.4 $\pm$ 0.6	20.5 $\pm$ 1.3	$P = 0.0001$	$P = 0.004$	ns
	Female	26.9 $\pm$ 0.5	25.6 $\pm$ 0.7	24.3 $\pm$ 0.7	21.2 $\pm$ 1.0	$P = 0.0001$	$P = 0.007$	ns
PN21	Male	34.3 $\pm$ 0.6	33.6 $\pm$ 1.0	31.6 $\pm$ 0.8	26.8 $\pm$ 1.6	$P = 0.0001$	$P = 0.012$	ns
	Female	33.8 $\pm$ 0.6	32.8 $\pm$ 1.0	31.0 $\pm$ 0.8	27.1 $\pm$ 1.2	$P = 0.0001$	$P = 0.014$	ns
PN24	Male	43.7 $\pm$ 1.1	42.3 $\pm$ 0.9	39.7 $\pm$ 1.1	33.8 $\pm$ 2.1	$P = 0.0001$	$P = 0.013$	ns
	Female	42.1 $\pm$ 0.8	40.4 $\pm$ 1.1	38.0 $\pm$ 1.0	34.3 $\pm$ 1.5	$P = 0.0001$	$P = 0.028$	ns
PN28	Male	58.7 $\pm$ 1.2	57.4 $\pm$ 1.1	54.5 $\pm$ 2.4	45.8 $\pm$ 2.7	$P = 0.0001$	$P = 0.015$	ns
	Female	54.9 $\pm$ 1.0	54.1 $\pm$ 1.4	51.6 $\pm$ 1.4	45.6 $\pm$ 1.8	$P = 0.0001$	$P = 0.024$	ns
PN35	Male	87.7 $\pm$ 1.7	86.6 $\pm$ 1.7	81.7 $\pm$ 1.3	73.3 $\pm$ 2.8	$P = 0.0001$	$P = 0.020$	ns
	Female	79.1 $\pm$ 1.2	77.8 $\pm$ 1.8	74.6 $\pm$ 1.4	69.1 $\pm$ 2.0	$P = 0.0001$	$P = 0.039$	ns

Table 3. Maternal and pup plasma, mammary and milk composition in the four cross-foster groups on postnatal day 6 in the four cross-foster groups. Data are analysed with a two-way ANOVA reporting differences between Pup and Mother groups with a Student's t-test used to identify where interactions lie. Data presented as the mean $\pm$ SEM with sex pooled per litter, where ns is not significant. Significant differences between Control and Restricted pups are indicated by an asterisk (* $P < 0.05$) and differences between sham operated (Control) and uteroplacental insufficiency surgery (Restricted) mothers are indicated with a double dagger ($\ddagger P < 0.05$).

Pup -on- Mother	Control -on- Control	Control -on- Restricted	Restricted -on- Control	Restricted -on- Restricted	Two-way ANOVA		
					Pup	Mother	Interaction
Maternal							
Body weight (g) (n = 8-9)	250.9±6.7	246.3±5.1	239.3±6.7	237.7±3.5	ns	ns	ns
Plasma PTHrP (pmol/l) (n = 7-9)	8.2±0.4	9.1±1.2	9.7±0.7	9.5±0.4	ns	ns	ns
Plasma Corticosterone (ng/ml) (n = 4-8)	593±59	726±106	682±71	737±37	ns	ns	P = 0.034
Mammary							
PTHrP mRNA (n = 3-6)	1.0±0.1	0.8±0.3	1.4±0.4	0.8±0.2	ns	ns	ns
α-lactalbumin mRNA (n = 5-7)	1.2±0.25	0.5±0.13	0.6±0.04	0.7±0.22	ns	ns	ns
β-casein mRNA (n = 5-7)	1.2±0.19	0.4±0.11	0.6±0.10	0.3±0.04	P = 0.001	P = 0.024	ns
Milk							
PTHrP (pmol/l) (n = 6-9)	1818±166	2958±592	1912±273	2341±434	ns	ns	ns
Na/K (n = 7-8)	7.6±1.2	6.5±1.6	5.8±1.0	7.4±1.5	ns	ns	ns
Ionic Ca (mmol/l) (n = 6-8)	8.9±0.6	8.7±1.0	11.2±0.8*	6.9±0.9‡	ns	P = 0.013	P = 0.020
Total Calcium (mmol/l) (n = 5-8)	64.7±4.0	65.8±3.7	52.0±10.9	53.7±4.9	P = 0.041	ns	ns
Total protein (mg/l) (n = 3-5)	28.2±4.4	22.0±3.7	27.9±7.5	23.8±2.9	ns	ns	ns
Lactose (mM) (n = 3-6)	30.2±7.9	38.4±3.8	25.4±6.8	28.8±9.0	ns	ns	ns
Pup							
Plasma PTHrP (pmol/l) (n = 6-9)	86.0±4.6	51.7±12.0	88.8±12.7	66.3±7.7	ns	P = 0.014	ns
Body total calcium (mmol/g) (n = 7-9)	0.081±0.001	0.076±0.002	0.073±0.002	0.073±0.001	P = 0.001	ns	ns

Table 4. Fatty acid composition in stomach contents consumed in milk presented as a cumulative total percentage of fatty acids on postnatal day 6 in the four cross-foster groups (n = 5-7 per group, with n = 1 representing data from 1 pooled litter). Data are analysed with a two-way ANOVA reporting differences between Pup (Control vs. Restricted) and Mother (sham operated (Control) vs. uteroplacental insufficiency surgery (Restricted)) groups with a Student's t-test used to identify where interactions lie. Data presented as the mean $\pm$ SEM with sex pooled per litter, where ns is not significant. Also see Table S1 for individual fatty acids.

Pup -on- Mother	Control -on- Control	Control -on- Restricted	Restricted -on- Control	Restricted -on- Restricted	Two-way ANOVA		
					Pup	Mother	Interaction
Fatty acids							
n-6	14.4 $\pm$ 0.4	17.4 $\pm$ 0.7	18.0 $\pm$ 0.7	19.6 $\pm$ 0.7	$P = 0.0001$	$P = 0.001$	ns
n-3	2.4 $\pm$ 0.09	2.4 $\pm$ 0.18	2.8 $\pm$ 0.16	3.2 $\pm$ 0.09	$P = 0.0001$	ns	ns
n-3:n-6	0.17 $\pm$ 0.004	0.14 $\pm$ 0.006	0.16 $\pm$ 0.010	0.16 $\pm$ 0.006	ns	ns	$P = 0.057$
Total LC-PUFA	16.8 $\pm$ 0.4	19.8 $\pm$ 0.8	20.8 $\pm$ 0.7	22.8 $\pm$ 0.8	$P = 0.0001$	$P = 0.002$	ns
Total LC-MUFA	22.4 $\pm$ 0.9	22.4 $\pm$ 1.4	24.4 $\pm$ 0.8	27.1 $\pm$ 1.8	$P = 0.016$	ns	ns
Saturated fatty acids							
Medium (6-12)	19.8 $\pm$ 1.0	21.1 $\pm$ 0.7	21.1 $\pm$ 0.6	18.9 $\pm$ 2.6	ns	ns	ns
Long (14-20)	40.4 $\pm$ 1.1	35.2 $\pm$ 2.1	32.5 $\pm$ 1.2	29.8 $\pm$ 0.5	$P = 0.0001$	$P = 0.017$	ns

Table S1 - related to Table 4. Fatty acid composition in stomach contents consumed in milk as a percentage of total of total fatty acids on postnatal day 6 in the four cross-foster groups (n = 5-7 per group, with n = 1 representing data from 1 pooled litter). Data are analysed with a two-way ANOVA reporting differences between Pup and Mother groups with a Student's t-test used to identify where interactions lie. Data presented as the mean $\pm$ SEM with sex pooled per litter, where ns is not significant. Significant differences between Control and Restricted pups are indicated with an asterisk (* $P < 0.05$; Student's t-test) and differences between sham operated (Control) and uteroplacental insufficiency surgery (Restricted) mothers are indicated with a double dagger ($\ddagger P < 0.05$; Student's t-test).

Pup -on- Mother		Control -on- Control	Control -on- Restricted	Restricted -on- Control	Restricted -on- Restricted	Two-way ANOVA		
						Pup	Mother	Interaction
Saturated fatty acids (%)								
Medium chain (%)								
8:0	Caprylic	1.15 $\pm$ 0.21	1.05 $\pm$ 0.19	1.37 $\pm$ 0.08	1.58 $\pm$ 0.48	ns	ns	ns
10:0	Capric	8.61 $\pm$ 0.48	8.44 $\pm$ 1.43	9.97 $\pm$ 0.39	9.12 $\pm$ 1.23	ns	ns	ns
12:0	Lauric	10.07 $\pm$ 0.34	8.74 $\pm$ 1.50	9.70 $\pm$ 0.26	8.24 $\pm$ 0.89	ns	ns	ns
Long chain (%)								
14:0	Myristic	12.44 $\pm$ 0.44	11.03 $\pm$ 0.89	9.55 $\pm$ 0.60	7.52 $\pm$ 0.82	$P = 0.0001$	$P = 0.029$	ns
15:0	Pentadecanoic	0.17 $\pm$ 0.01	0.24 $\pm$ 0.01	0.22 $\pm$ 0.03	0.21 $\pm$ 0.05	ns	ns	ns
16:0	Palmitic	24.34 $\pm$ 0.76	21.06 $\pm$ 1.24	19.63 $\pm$ 0.63	18.85 $\pm$ 0.61	$P = 0.001$	$P = 0.040$	ns
17:0	Margaric	0.18 $\pm$ 0.01	0.17 $\pm$ 0.03	0.19 $\pm$ 0.02	0.18 $\pm$ 0.05	ns	ns	ns
18:0	Stearic	3.14 $\pm$ 0.24	2.57 $\pm$ 0.04	2.82 $\pm$ 0.05	3.02 $\pm$ 0.22	ns	ns	$P = 0.023$
20:0	Arachidic	0.10 $\pm$ 0.02	0.09 $\pm$ 0.02	0.10 $\pm$ 0.02	0.07 $\pm$ 0.03	ns	ns	ns
Monounsaturated fatty acids (%)								
12:1	Lauroleic	0.00 $\pm$ 0.00	0.28 $\pm$ 0.11 $\ddagger$	0.05 $\pm$ 0.04	0.17 $\pm$ 0.17	ns	$P = 0.050$	ns
16:1	Palmitoleic	0.93 $\pm$ 0.07	0.97 $\pm$ 0.08	1.06 $\pm$ 0.11	0.81 $\pm$ 0.13	ns	ns	ns
17:1	Heptadecenoic acid	0.05 $\pm$ 0.03	0.10 $\pm$ 0.02	0.06 $\pm$ 0.03	0.03 $\pm$ 0.03	ns	ns	ns
18:1n-9	Oleic	20.87 $\pm$ 0.82	20.58 $\pm$ 1.24	22.60 $\pm$ 0.72	25.37 $\pm$ 1.92	$P = 0.014$	ns	ns
20:1n-9	Gondoic	0.51 $\pm$ 0.03	0.50 $\pm$ 0.04	0.59 $\pm$ 0.02	0.69 $\pm$ 0.06	$P = 0.002$	ns	ns
LC-PUFA (n-6) (%)								
18:2n-6	Linoleic	11.79 $\pm$ 0.25	14.12 $\pm$ 0.43	14.38 $\pm$ 0.44	15.35 $\pm$ 0.41	$P = 0.0001$	$P = 0.001$	ns
18:3n-6	γ -linolenic	0.20 $\pm$ 0.01	0.25 $\pm$ 0.01 $\ddagger$	0.23 $\pm$ 0.02	0.18 $\pm$ 0.05*	ns	ns	$P = 0.035$
20:2n-6	Ecosatrienoic	0.53 $\pm$ 0.02	0.58 $\pm$ 0.03	0.68 $\pm$ 0.03	0.78 $\pm$ 0.04	$P = 0.0001$	$P = 0.038$	ns
20:3n-6	Dihomo- γ -linolenic	0.35 $\pm$ 0.02	0.40 $\pm$ 0.02	0.35 $\pm$ 0.05	0.46 $\pm$ 0.03	ns	$P = 0.025$	ns
20:4n-6	Arachidonic	1.03 $\pm$ 0.06	1.33 $\pm$ 0.12	1.46 $\pm$ 0.10	1.73 $\pm$ 0.17	$P = 0.002$	$P = 0.025$	ns
22:4n-6	Docosatetraenoic	0.49 $\pm$ 0.04	0.69 $\pm$ 0.10	0.85 $\pm$ 0.07	1.07 $\pm$ 0.12	$P = 0.0001$	$P = 0.030$	ns
LC-PUFA (n-3) (%)								
18:3n-3	α -linolenic	1.40 $\pm$ 0.06	1.48 $\pm$ 0.09	1.45 $\pm$ 0.13	1.55 $\pm$ 0.08	ns	ns	ns
20:5n-3	Eicosapentaenoic	0.21 $\pm$ 0.01	0.17 $\pm$ 0.03	0.18 $\pm$ 0.03	0.17 $\pm$ 0.04	ns	ns	ns
22:5n-3	Docosapentaenoic	0.36 $\pm$ 0.03	0.38 $\pm$ 0.04	0.48 $\pm$ 0.03	0.61 $\pm$ 0.06	$P = 0.0001$	ns	ns
22:6n-3	Docosahexaenoic	0.41 $\pm$ 0.03	0.45 $\pm$ 0.06	0.68 $\pm$ 0.06	0.85 $\pm$ 0.10	$P = 0.0001$	ns	ns